MabVax Therapeutics Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (25)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“MabVax Therapeutics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by MabVax Therapeutics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in preclinical phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“MabVax Therapeutics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“MabVax Therapeutics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by MabVax Therapeutics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in preclinical phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“MabVax Therapeutics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. MabVax Therapeutics

  1.1 Business Overview

  1.2 MabVax Therapeutics Cancer Pipeline Overview

 

2. MabVax Therapeutics Cancer Drugs in Research Phase

  2.1 Chimeric Antigen Receptor T Cell Therapeutics - MabVax/MSKCC

 

3. MabVax Therapeutics Cancer Drugs in Preclinical Phase

  3.1 HuMab 5B1 Radioimmunotherapy – MabVax

  3.2 Anticancer Monoclonal Antibodies - MabVax/MSKCC

  3.3 Ezatiostat Analogues – MabVax

  3.4 Alkylating Agents – MabVax

 

4. MabVax Therapeutics Cancer Drugs in Phase-I

  4.1 MVT 2163

  4.2 MVT 5873

 

5. MabVax Therapeutics Cancer Drugs in Phase-I/II

  5.1 Neuroblastoma Vaccine - MabVax/MSKCC

 

6. MabVax Therapeutics Cancer Drugs in Phase-II

  6.1 Ovarian Cancer Vaccine - MabVax/MSKCC

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 Breast Cancer Vaccine - MabVax/MSKCC

  7.2 Small Cell Lung Cancer Vaccine - MabVax/MSKCC

  7.3 Melanoma Vaccine - MabVax/Memorial Sloan-Kettering Cancer Center


Figure 1-1: MabVax Therapeutics Cancer Pipeline by Phase (%)

Figure 1-2: MabVax Therapeutics Cancer Pipeline by Phase (Number)